Teza Capital Management LLC Sells 14,550 Shares of DexCom, Inc. (NASDAQ:DXCM)

Teza Capital Management LLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 50.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,081 shares of the medical device company's stock after selling 14,550 shares during the quarter. Teza Capital Management LLC's holdings in DexCom were worth $1,095,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Private Trust Co. NA raised its position in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares in the last quarter. Optiver Holding B.V. acquired a new position in DexCom during the fourth quarter valued at approximately $33,000. TD Private Client Wealth LLC lifted its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC lifted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter valued at $38,000. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on DXCM shares. Piper Sandler dropped their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Robert W. Baird cut their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Finally, Barclays raised their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $98.00.

Insider Activity

In related news, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This trade represents a 4.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This represents a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 over the last quarter. Insiders own 0.32% of the company's stock.

DexCom Stock Down 0.1%

DXCM stock traded down $0.06 during mid-day trading on Thursday, reaching $84.83. 1,693,852 shares of the company traded hands, compared to its average volume of 4,352,228. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm's 50 day moving average price is $72.99 and its 200 day moving average price is $77.92. The stock has a market cap of $33.26 billion, a price-to-earnings ratio of 59.32, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $131.76.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the firm earned $0.32 EPS. The firm's quarterly revenue was up 12.5% on a year-over-year basis. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.